Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Many women may be wondering what this means for them in light of the Supreme Court's decision on Friday regarding a crucial medication used in medical abortions.
Read Full NewsA retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.
For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.
Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.
Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.
1.
Three out of ten breast cancers detected between screenings, study finds
2.
Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation
3.
Can Alternating Venetoclax Regimens Improve AML Outcomes?
4.
Limits to Anti-Nausea Pill Coverage Wear on Cancer Patients and Doctors
5.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
1.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
2.
Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology
3.
Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology
4.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
5.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
3.
Navigating the Complexities of Ph Negative ALL - Part IX
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge